Mitochondrial modifier (ABHD18)
Asset
- Stage
- Preclinical
- Modality
- Oligonucleotide
- Target
- ABHD18
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Cardiomyopathy
Preclinical, scenicbiotech.com, 10 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.